The End Of The FDA Approvals Boom? Fewer Applications Are A COVID-19 Consequence
Applications for US FDA approval are lower than in recent history, portending a lean 2021.
You may also be interested in...
Keeping Track: Biogen’s Aducanumab Headlines Midsummer Submission Round-Up
The latest application submission news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA Not Missing Assessment Goals, But Guidance Reminds That It’s Possible
New Q&A guidance also states that its near-term focus for resources will be on coronavirus and some other conditions.
Keeping Track Of Submissions: Myovant’s First Relugolix NDA; Merck Resubmits Longer Keytruda Dosing; Biogen Adjusts Aducanumab Rolling Target
The latest news and highlights about submissions for US approval, from the Pink Sheet FDA Performance Tracker.